Prevnar 13 Basics:
What Prevnar 13 Is Used For:
Prevnar 13 Facts:
Who Should Get Prevnar 13:
- Children who have already received one or more doses of Prevnar 7 will simply finish their vaccine schedule with Prevnar 13.
- An extra dose of Prevnar 13 is also recommended for all children between the ages of 14 to 59 months, even if they have already received 4 doses of Prevnar 7.
- Children at high risk for invasive pneumococcal disease, such as those with medical conditions like chronic heart or lung disease, should get an extra dose of Prevnar 13 through the age of 71 months. Children at the highest risk for invasive pneumococcal disease, such as those with HIV or sickle cell disease, need at least one dose of Prevnar 13 before they turn 18 years old. This is in addition to the pneumovax vaccine.
Prevnar 13 Side Effects:
What You Need To Know:
- Like most vaccines in the current childhood immunization schedule, Prevnar 13 does not contain the preservative thimerosal.
- Children should not be given Prevnar 13 if they have had a severe allergic reaction to any component of Prevnar 7, Prevnar 13, or any vaccine that contains the diphtheria toxoid.
CDC. ACIP Provisional Recommendations for Use of 13-Valent Pneumococcal Conjugate Vaccine ( PCV13) Among Infants and Children. MMWR 2010, 59:258-261: March 12, 2010.
Morbidity and Mortality Weekly Report. Licensure of a 13-Valent Pneumococcal Conjugate Vaccine (PCV13) and Recommendations for Use Among Children -- Advisory Committee on Immunization Practices (ACIP), 2010. MMWR March 12, 2010, Vol 59, #9.